Show simple item record

dc.contributor.authorBrahmer, JRen_US
dc.contributor.authorRodríguez-Abreu, Den_US
dc.contributor.authorRobinson, AGen_US
dc.contributor.authorHui, Ren_US
dc.contributor.authorCsőszi, Ten_US
dc.contributor.authorFülöp, Aen_US
dc.contributor.authorGottfried, Men_US
dc.contributor.authorPeled, Nen_US
dc.contributor.authorTafreshi, Aen_US
dc.contributor.authorCuffe, Sen_US
dc.contributor.authorO’Brien, Men_US
dc.contributor.authorRao, Sen_US
dc.contributor.authorHotta, Ken_US
dc.contributor.authorDeitz, ACen_US
dc.contributor.authorLubiniecki, GMen_US
dc.contributor.authorZhang, Jen_US
dc.contributor.authorRangwala, Ren_US
dc.contributor.authorReck, Men_US
dc.date.accessioned2018-02-20T13:55:31Z
dc.date.issued2017-01en_US
dc.identifier.citationJournal of Thoracic Oncology, 2017, 12 (1), pp. S8 - S9en_US
dc.identifier.issn1556-0864en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1432
dc.identifier.doi10.1016/j.jtho.2016.11.010en_US
dc.format.extentS8 - S9en_US
dc.languageenen_US
dc.language.isoenen_US
dc.publisherElsevier BVen_US
dc.titlePL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.jtho.2016.11.010en_US
rioxxterms.licenseref.startdate2017-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJournal of Thoracic Oncologyen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume12en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record